Privately held Evox Therapeutics raised £35.5m ($45.4m) of new capital in a series B financing round, adding to the £10m injected by a series A seed financing a year ago.
Flush with fresh funds from a series B financing, two-year old exosome specialist Evox Therapeutics will now progress its lead preclinical program into man and seek more collaborations with big pharma to augment the two it already has, the Oxford-based biotech's CEO told Scrip.
Keeping to its business strategy outlined to Scrip in January, Evox raised £35.5m ($45
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
